Prognostic factors for overall survival and safety of trans-arterial chemoembolization (TACE) with irinotecan-loaded drug-eluting beads (DEBIRI) in patients with colorectal liver metastases
, , , , y
30 mar 2024
Acerca de este artículo
Categoría del artículo: Research Article
Publicado en línea: 30 mar 2024
Páginas: 214 - 220
Recibido: 13 dic 2023
Aceptado: 06 mar 2024
DOI: https://doi.org/10.2478/raon-2024-0023
Palabras clave
© 2024 Maja Sljivic et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
FIGURE 1.
FIGURE 2.
FIGURE 3.
FIGURE 4.
Patient demographics and clinicopathological features
| Median (range) | 68 (34–85) |
| Sex | |
| Male | 22 (73) |
| Female | 8 (27) |
| Primary tumour | |
| Colon | 16 (53) |
| Rectum | 14 (47) |
| ECOG performance status | |
| 0 | 18 (60) |
| 1 | 9 (30) |
| 2 | 3 (10) |
| Liver metastases | |
| Unilobar | 17 (57) |
| Bilobar | 13 (43) |
| ≤ 4 lesions | 19 (63) |
| > 4 lesions | 11 (37) |
| Previous chemotherapy | |
| Yes | 17 (57) |
| No | 13 (43) |
Univariate analysis – influence of probable prognostic factors on overall survival
| Age ≤ 65 years | 11 (37) | 15.2 | 8.5–21.8 | 0.284 |
| Age > 65 years | 19 (63) | 21.6 | 4.7–38.4. | |
| Colon | 16 (53) | 23.7 | 16.8–30.5 | 0.145 |
| Rectum | 14 (47) | 14.1 | 6.8–21.4 | |
| ECOG 0 | 18 (60) | 19.8 | 11.3–28.4 | 0.805 |
| ECOG 1 or 2 | 12 (40) | 17.4 | 10.0–29.7 | |
| Previous chemotherapy | 17 (57) | 17.4 | 11.0–23.7 | 0.472 |
| No previous chemotherapy | 13 (43) | 21.6 | 3.8–39.4 | |
| Unilobar disease | 17 (57) | 23.5 | 7.4–39.6 | 0.106 |
| Bilobar disease | 13 (43) | 15.2 | 1.9–28.4 | |
| ≤ 4 liver lesions | 19 (63) | 15.5–31.5 | ||
| > 4 liver lesions | 11 (37) | 0.3–21.3 | ||
| CEA ≤ 5 µg/L before the first DEBIRI TACE | 5 (27) | 17.4 | 5.9–28.9 | 0.591 |
| CEA > 5 µg/L before the first DEBIRI TACE | 22 (73) | 15.2 | 9.2–21.1 | |
| Increase of serum CEA after first DEBIRI TACE | 10 (33) | 14.1 | 7.3–20.9 | 0.037 |
| Decrease of serum CEA after first DEBIRI TACE | 12 (40) | 24.7 | 7.0–42.4 | |
| CEA stayed the same | 1 (3) | 25.5 | ||
| CA 19-9 ≤ 37 kU/L before first DEBIRI TACE | 16 (53) | 15.2 | 10.1–20.2 | 0.393 |
| CA 19-9 > 37 kU/L before first DEBIRI TACE | 11 (47) | 17.4 | 0.5–34.2 | |
| Increase of serum CA 19-9 after first DEBIRI TACE | 11 (48) | 15.2 | 11.7–18.7 | 0.583 |
| Decrease of serum CA 19-9 after first DEBIRI TACE | 10 (43) | 19.8 | 0.0–44.9 | |
| CA 19-9 stayed the same | 2 (9) | 7.4 |